Insulet Appoints Peter J. Devlin as Chief Commercial Officer

BEDFORD, Mass., Aug. 17 /PRNewswire-FirstCall/ --Insulet Corporation (Nasdaq:
PODD), the leader in tubing-free insulin pump technology with its OmniPod(R)
Insulin Management System, today announced the appointment of Peter J. Devlin
as Chief Commercial Officer. In this newly created role, Mr. Devlin will lead
the Company's Sales and Marketing, Business Development, Clinical Research and
Customer Care operations.

"Peter brings a distinguished track record in the diabetes and medical device
industries and we are extremely pleased to have him join Insulet's management
team," said Duane DeSisto, president & chief executive officer of Insulet.
"Peter's proven ability to develop and implement successful commercial
strategies globally will be invaluable to Insulet as we continue to grow our
core insulin pump business and expand into new opportunities for the
easy-to-use OmniPod System."

Mr. Devlin spent the last 11 years at Abbott Laboratories, most recently
serving as Divisional Vice President of Global Strategic Marketing, Diabetes
Care. In this role, he was responsible for the development of commercial
strategies, global brand management, market research, area strategic
marketing, and business analytics and forecasting. Previously, Mr. Devlin
served as Marketing Manager of i-STAT Corporation, a point-of-care blood
analysis systems company, which was acquired by Abbott. Prior, Mr. Devlin
spent eight years at C.R. Bard Inc., where he held various product management
and engineering roles of increasing responsibility. Mr. Devlin holds a
Bachelor of Science degree in Mechanical Engineering from the University of
Massachusetts.

"I am eager to join Insulet at this exciting time as the OmniPod System
transitions from being a new technology to the standard of care in the insulin
pump market," said Mr. Devlin. "I am also excited to help Insulet realize the
promise of its innovative delivery system in a broad range of therapies."

About Insulet Corporation

Insulet Corporation is an innovative medical device company dedicated to
improving the lives of people with diabetes. The Company's OmniPod Insulin
Management System is a revolutionary, discreet and easy-to-use insulin
infusion system that features two easy-to-use parts with no tubing and
fully-automated cannula insertion. Through the OmniPod System, Insulet seeks
to expand the use of insulin pump therapy among people with insulin-dependent
diabetes. Founded in 2000, Insulet is based in Bedford, MA.

Contact:
Stephanie Marks for Insulet Corporation
ir@insulet.com
877-PODD-IR1 (877-763-3471)

SOURCE Insulet Corporation

Stephanie Marks for Insulet Corporation, ir@insulet.com, +877-PODD-IR1
(877-763-3471)